Barber Daniel, the President and CEO of Aquestive Therapeutics, Inc., has reported a significant stock transaction. On October 15, 2026, he sold 25,000 shares of common stock at an average price of $4.2240. This transaction is noteworthy as it reflects the ongoing financial maneuvers of a key executive in the company.
Aquestive Therapeutics, Inc. is classified under the SIC code for Pharmaceutical Preparations. The company operates within the pharmaceutical industry, which is known for its rapid advancements and competitive landscape. The recent stock sale by Barber Daniel may influence how investors and analysts view the company's current financial health and future prospects.
According to the SEC filing (accession number 0001214659-26-012986), the transaction was classified as a sale, with the shares disposed of at prices ranging from $4.03 to $4.68 each. The weighted average price per share was noted as $4.2240. Following this transaction, Barber Daniel retains ownership of 627,317 shares.
This transaction may affect various stakeholders, including investors, analysts, and the broader market. As the CEO engages in stock sales, it could prompt discussions about the company's strategy and financial positioning within the pharmaceutical sector.
The filing does not specify what happens next regarding further transactions or company announcements.
Transaction Details
The SEC filing indicates that Barber Daniel's stock sale was executed on October 15, 2026, with a total of 25,000 shares disposed of. The transaction was categorized as a sale, and it is noted that the prices of the shares sold varied between $4.03 and $4.68 each.
Following the sale, Barber Daniel retained a significant holding of 627,317 shares of common stock in Aquestive Therapeutics, Inc. This retention of shares may reflect his continued confidence in the company's future performance.
Company Background
Aquestive Therapeutics, Inc., incorporated in Delaware, operates in the pharmaceutical sector under the SIC code for Pharmaceutical Preparations. The company is headquartered at 184 Liberty Corner Road, Suite 305, Warren, NJ, and has a fiscal year that ends on December 31.
"The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price."
While the filing provides detailed information about the transaction, it does not include any insights into Barber Daniel's future plans regarding additional stock transactions or any specific strategic initiatives for Aquestive Therapeutics, Inc.